Board of Directors
The Board consists of the ordinary members: Gisela Sitbon (Chairman), Laura Chirica, Henrik Didner, Rolf Ehrnström, Ted Elvhage and Simon Turner. The Board is elected annually at the Annual General Meeting for the period until the next Annual General Meeting has been held.
Gisela Sitbon, PhD
Chairman since 2020
Gisela Sitbon has a research background within molecular biology, combined with more than 25 years of senior level experience from the life science industry. This includes business development and operational positions, as well as co-founding and managing a service-providing diagnostic company, later acquired by Capio. Currently holds several chair positions and board appointments in private and stock market listed companies.
Born: 1958
Education: Doctor of Medical Sciences (PhD), Karolinska Institutet.
Previous experience: Board work in public, private and owner-managed companies. Sowing and growth financing in the Life Science sector. Entrepreneur, CEO and leading positions, such as business development, R&D and quality management systems, in innovative Life Science companies.
Other assignments: Gisela Sitbon is Chairman of the Board of Amplicon AB, Emplicure AB, Emplipharm AB and Nanologica AB and a Board member of Annexin Pharmaceuticals AB, Encare AB and UU Invest AB. She is also owner and a Board member of Sitbon Bioscience Partner ZENZ AB.
Holding: 56,000 shares
Gisela Sitbon is independent in relation to the Company and the company management and the Company’s major shareholders, respectively.
Henrik Didner, PhD
Director since 2018
Co-founder, owner and working chairman of the Swedish leading fund management firm Didner & Gerge. Other current commitments include the position as chairman for Uppsala University Invest and various board member positions. Henrik Didner holds a PhD in Business Administration from Uppsala University.
Born: 1958
Education: PhD, Uppsala University.
Previous experience: Fund management since 1994.
Other assignments: Henrik Didner is co-owner and Chairman of the Board of Didner & Gerge Fonder AB and Monesi Förvaltnings AB and Chairman of the Board of Uppsala universitet Invest AB. Henrik is also a Board member of G-Förvaltning AB, Oncodia AB, Axel Johansson Uppsala Nya Tidning Förvaltning AB, CLA Sweden AB, Baracken AB and VBN Components AB.
Holding: 2,282,436 shares (via Monesi Förvaltnings AB).
Henrik Didner is independent in relation to the company and the company management, but is not independent in relation to the company’s major shareholders.
Rolf Ehrnström
Director since 2020
Rolf Ehrnström has extensive R&D leadership experience from biotech and diagnostic companies like e.g. Amersham Pharmacia Biotech, Dako (acquired by Agilent) and the microfluidics pioneer company Gyros. Today, Rolf Ehrnström serves on the board of directors for various innovation-driven life science companies and is appointed independent partner at Ventac Partners.
Born: 1953
Education: Master of Science in Biochemistry and Biotechnology from KTH Stockholm.
Previous experience: 20 years in leading positions in R&D at Pharmacia Biotech, VP R&D at Gyros AB and CVP R&D at Dako A/S.
Other assignments: Rolf Ehrnström is Chairman of the Board and CEO of Reomics AB. Rolf is also a Board member of Scandinavian Chemotech AB, Fluimedix A/S, ZipPrime Oy and LSCancer Diagnostics Oy. In addition, he serves as a consultant within life science and is a member of various funding agencies (Vinnova, EITH, NOME and Uppsala Bio-X).
Holding: 18,659 shares (via Reomics AB)
Rolf Ehrnström is independent in relation to the company and the company management and the company’s major shareholders, respectively.
Laura Chirica, PhD
Director since 2021
Laura Chirica holds an PhD in biochemistry and has over 20 years’ experience of global commercial positions in the bioprocess, biotech and diagnostics sector. In her previous role as Chief Commercial Officer for Immunovia, she played a key role in the commercialisation of Immunovia's first product and the company’s journey to the market. She is today CEO of Cellevate and Board member of Pre-Diagnostics.
Born: 1968
Education: Doctor of Biochemistry (PhD), Umeå University.
Previous experience: CCO for Immunovia AB, VP Sales and Marketing at Euro Diagnostica AB, Director Purification Technologies Europe at Sartorius Stedim, Global Marketing Director at Dako A/S and Global Marketing Program Manager at GE Healthcare.
Other assignments: Laura Chirica is CEO of Cellevate AB and Board member of Pre-Diagnostics AS.
Holding: 7,035 shares
Laura Chirica is independent in relation to the company and the company management and the company’s major shareholders, respectively.
Hilja Ibert, PhD
Director since 2023
Hilja Ibert brings more than 30 years of experience from the clinical diagnostics industry at international companies like Hologic, Becton Dickinson and bioMérieux, including Vice President and General Manager positions within the business areas of Diagnostic systems and Bioscience. She is today chairperson, earlier CEO of the Norwegian listed company Gentian Diagnostics, and Board member of French VitaDX International.
Born: 1960
Education: PhD in Nutrition Science from the University of Bonn.
Previous experience: More than 30 years within the clinical diagnostics industry including CEO of miDiagnostics, VP/GM positions at Hologic and Becton Dickinson, Corporate Marketing Manager at bioMérieux, and most recently CEO of Gentian Diagnostics ASA.
Other assignments: Chairperson of Gentian Diagnostics ASA, Board member of VitaDX International.
Holding: –
Hilja Ibert is independent in relation to the company and the company management and the company’s major shareholders, respectively.
Nedal Safwat, PhD
Director since 2023
Nedal Safwat is an accomplished leader in the clinical diagnostic industry with 20+ years of global experience. Nedal Safwat has held diverse roles, gaining a comprehensive understanding of the industry. He has successfully led commercial teams, developing strategies for microbiology applications such as bacterial identification, antibiotic susceptibility testing, resistance, and sepsis detection.
Born: 1975
Education: Bachelor of Science and PhD in Biochemistry from North Carolina State University, USA.
Previous experience: VP Marketing and Business Development at Chromacode Inc, Executive Director, Director of Global Marketing and Director of Clinical Marketing at bioMérieux.
Other assignments: VP and Head of Molecular Diagnostics North America at Qiagen, US.
Holding: –
Nedal Safwat is independent in relation to the company and the company management and the company’s major shareholders, respectively.